Median age was 52 years (ranging from 21 to 71). RESULTS Patients’ characteristicsīetween July 2010 and December 2014, a total of 88 HER2-positive patients with breast cancer were enrolled in the present cohort. Thus, in our study, data of patients with HER2-positive and lymph node positive disease, who were treated with carboplatin, paclitaxel concurrently with trastuzumab was retrospectively analyzed, in order to identify effective predictive markers for pCR that could be used in the next future for treatment decision making. The effectiveness of this regimen used for this type of disease was not established, and the predictive factors of pCR have not been clarified yet. However, compared to lymph node negative breast cancer, tumor with HER2 positive and lymph node-positive was a subtype of biological and anatomic more aggressive disease. Carboplatin, instead of anthracyclines, has also been implemented to NAC regimens in an attempt to obtain a higher pCR rate, and indeed, this regimen containing taxane, carboplatin and trastuzumab has been confirmed to be effective in HER2 positive disease. However, the pCR rate of neoadjuvant chemotherapy (NAC) using taxanes and trastuzumab was not high, ranging from 20 to 40% in early studies. The superiority of the addition of trastuzumab to a taxane-based chemotherapy regimen is supported by data from metastatic, neoadjuvant and adjuvant studies. The combination of a chemotherapeutic regimen and a recombinant monoclonal antibody against HER2, trastuzumab, has formed the cornerstone of therapy for HER2-positive breast cancer. Clinico-pathological characteristics were compared and analyzed, and univariate and multivariate analyses were performed to detect the predictive factors of pCR.Ĭonclusions: Preoperative PCH regimen was an effective neoadjuvant therapy in HER2 positive and axillary lymph node positive patients, and patients coexisting with HR-negative and high Ki67 index may benefit more from this regimen.Īmplification of HER2 is identified in approximately 20–25% of human breast cancers. Materials and Methods: 88 consecutive Chinese HER2-positive/axillary lymph node-positive breast cancer patients with neodjuvant therapy regimen containing paclitaxel, carboplatin and trastuzumab were divided into two groups: pathological complete response (pCR) or non-pCR group. Further investigation found that patients with HR-negative/high Ki67 index had higher pCR rate, compared to other patients (HR = 7.583, 95% CI 2.503−22.974, p < 0.001). Patients with and without pCR were similar in term of age, BMI, menstrual status, family history, treatment cycles and tumor characteristics (laterality and size of tumor). Objective: This study was performed to investigate the proportion as well as the predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab (PCH). Received: NovemAccepted: ApPublished: May 19, 2017 Keywords: breast cancer, neoadjuvant chemotherapy, human epidermal growth factor receptor 2 (HER2), Ki67, pathological complete response (pCR) *These authors contributed equally to this work Jinhua Ding 1, 2, *, Yinlong Yang 2, *, Li Jiang 3, Weizhu Wu 1 and Zhiming Shao 2ġDepartment of Breast and Thyroid Surgery, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, ChinaĢDepartment of Breast Surgery, Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, ChinaģDepartment of Emergency, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo, China
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |